Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 18/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | CSF1R | P07333 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | FLT1 | P17948 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528722 | 0.90 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL15529379 | 0.87 | RXFP1 (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL5140586 | 0.85 | RXFP1 (0.74) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL4976103 | 0.81 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL29356168 | 0.81 | KDR (1.00) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL18893146 | 0.81 | RXFP1 (0.81) | RXFP1 | |
| SCHEMBL4978213 | 0.81 | KDR (0.79) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL2489551 | 0.80 | ABL1 (0.78) | RXFP1ABL1EGFRCSF1RPDGFRB | |
| SCHEMBL27609471 | 0.80 | PTGS1 (0.60) | RXFP1DDR2 | |
| SCHEMBL1863665 | 0.80 | RXFP1 (0.80) | RXFP1ABL1EGFRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269988-B1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2012-05-23 | — | — | EP | claimed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | claimed |
| CN-1578768-A | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | claimed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | claimed |
| EP-1446381-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2004-08-18 | — | — | EP | claimed |
| WO-2003040101-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | claimed |
| EP-2269988-B1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| CN-100467450-C | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| CN-1578768-A | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | RXFP1 317/4885ABL1 3635/4885EGFR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.